Followers | 785 |
Posts | 128093 |
Boards Moderated | 9 |
Alias Born | 09/26/2011 |
Monday, February 10, 2014 10:46:24 AM
- AMARQ holds 5 U.S. patents related to Interferon use
- The company has been successful in acquiring settlements in lawsuits over their patents
- Interferons can be used to treat several kinds of cancers, AIDS, Fibromyalgia, Multiple Sclerosis, HPV, and other autoimmune diseases.
- GMR Data concluded that the cancer-treatment industry has sales upwards to $77.4 billion annually, and that is expected to grow to $143.7 billion by 2023, which means the interferon market for AMARQ has great potential.
- The company is currently seeking regulatory (FDA and others) approval of its low-dose oral interferon treatments for both influenza and hepatitis C viral infections.
- The company trades publicly on the OTC markets in the U.S., and on German markets as well in the Frankfurt, Stuttgart, Berlin-Bremen, and Xetra exchanges.
- Amarillo is headed by Stephen T. Chen, a doctor with over 30 years of experience in pharmacology. This includes finding and developing joint venture agreement opportunities, executing business strategy, and leading start-up companies through regulatory requirements.
- The market capitalization is only $395,711.
- As of the most recent 10-Q, there are only 73.5 million shares outstanding, which means that AMARQ has a very low float.
- Recent data has shown that low-dose interferon-alpha (like AMARQ specializes in) can be used to reduce pulmonary damage in cases where patients are infected with highly pathogenic influenza virus (avian flu, swine flu, and others.
- Following research by Hemispherx Biopharma that stated the importance in using interferons to treat influenza, interferon patents are now in focus by major pharmaceutical companies. AMARQ holds five of these types of patents, which could prove to be a very valuable asset to the company when bigger firms are seeking similar patents.
Recent AIMD News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:10:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:20:42 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 09:10:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:11:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:11:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:10:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:10:37 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/15/2024 07:02:16 PM
- Small-Cap Growth Virtual Investor Conference Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 02/08/2024 01:35:00 PM
- Small-Cap Growth Virtual Investor Conference Agenda Announced for February 7th, 2024 • GlobeNewswire Inc. • 02/06/2024 02:51:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:54:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:50:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:50:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:50:45 PM
- Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th • GlobeNewswire Inc. • 02/01/2024 01:35:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/29/2024 09:10:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:32:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:12:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:11:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:10:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/19/2023 05:15:08 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/15/2023 10:22:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 02:09:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM